Brief: Essex Bio-Technology Says Unit Agreed To Subscribe For Subscription Shares Of Antikor
July 19 (Reuters) - Essex Bio-Technology Ltd 1061.HK :
* ESSEX BIO-INVESTMENT AGREED TO SUBSCRIBE FOR SUBSCRIPTION
SHARES
OF ANTIKOR AT AGGREGATE CONSIDERATION OF UP TO US$3.1 MILLION
* ESSEX BIO-INVESTMENT AND ANTIKOR BIOPHARMA WILL ENTER
INTO IP
LICENCE AGREEMENT
Source text for Eikon: ID:nHKS9MGMTJ
Further company coverage: 1061.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Essex Bio-Technology
See all newsHong Kong's Essex Bio-Technology H1 revenue falls
Brief: Essex Bio-Technology Posts HY Profit Of HK$110.7 MLN
Brief: Essex Bio-Technology Expects 10% Revenue And 30% Profit Decrease For HY
Brief: Shanghai Henlius Biotech Says Phase 3 Study Of HLX04-O For WAMD Meets Primary Endpoint
Brief: Essex Bio-Technology Posts Final Dividend Of HK$0.07 Per Share